Andra AP fonden Sells 118,500 Shares of Abbott Laboratories $ABT

Andra AP fonden lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 36.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 206,708 shares of the healthcare product maker’s stock after selling 118,500 shares during the quarter. Andra AP fonden’s holdings in Abbott Laboratories were worth $21,223,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Summit Asset Management LLC raised its stake in Abbott Laboratories by 8.8% during the 1st quarter. Summit Asset Management LLC now owns 4,305 shares of the healthcare product maker’s stock worth $442,000 after acquiring an additional 350 shares during the period. Glenview Trust Co lifted its stake in shares of Abbott Laboratories by 0.9% during the 1st quarter. Glenview Trust Co now owns 92,145 shares of the healthcare product maker’s stock valued at $9,461,000 after buying an additional 797 shares in the last quarter. Long Road Investment Counsel LLC boosted its holdings in Abbott Laboratories by 12.6% in the 1st quarter. Long Road Investment Counsel LLC now owns 13,545 shares of the healthcare product maker’s stock worth $1,391,000 after buying an additional 1,521 shares during the period. Cura Wealth Advisors LLC boosted its holdings in Abbott Laboratories by 0.8% in the 1st quarter. Cura Wealth Advisors LLC now owns 229,627 shares of the healthcare product maker’s stock worth $23,576,000 after buying an additional 1,754 shares during the period. Finally, Johnson Financial Group Inc. increased its stake in Abbott Laboratories by 1.6% in the 1st quarter. Johnson Financial Group Inc. now owns 57,182 shares of the healthcare product maker’s stock worth $5,871,000 after buying an additional 893 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.0%

ABT stock opened at $101.72 on Tuesday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The stock has a market capitalization of $177.18 billion, a price-to-earnings ratio of 32.92, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61. The firm’s fifty day simple moving average is $90.28 and its two-hundred day simple moving average is $101.84.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business’s revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the acquisition, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ABT shares. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday. Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 7th. TD Cowen reiterated a “buy” rating and issued a $115.00 price target on shares of Abbott Laboratories in a report on Friday. Citigroup lifted their target price on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday. Finally, Evercore cut their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $118.61.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.